These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 34042340)
21. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872 [TBL] [Abstract][Full Text] [Related]
22. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL; J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591 [TBL] [Abstract][Full Text] [Related]
23. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]
24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. Ortega Martínez de Victoria E Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604 [No Abstract] [Full Text] [Related]
25. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions. Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909 [TBL] [Abstract][Full Text] [Related]
26. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526 [TBL] [Abstract][Full Text] [Related]
27. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. Brandts J; Ray KK Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819 [TBL] [Abstract][Full Text] [Related]
28. New Drugs for Lowering LDL-Cholesterol. Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561 [TBL] [Abstract][Full Text] [Related]
29. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Fitzgerald G; Kiernan T Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):567-578. PubMed ID: 29979908 [TBL] [Abstract][Full Text] [Related]
30. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
31. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
32. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Gebauer K; Reinecke H Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075 [TBL] [Abstract][Full Text] [Related]
33. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS; Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315 [TBL] [Abstract][Full Text] [Related]
34. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors]. Avci A; Demir K; Altunkeser BB Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363 [TBL] [Abstract][Full Text] [Related]
35. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212 [TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825 [TBL] [Abstract][Full Text] [Related]